Compare Citius Pharmaceuticals Inc (CTXR) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Under Armour Inc Class A — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Under Armour Inc Class A trades at $6.61 (market cap $2.79B). The key difference: Under Armour Inc Class A is far larger — about 190.6× Citius Pharmaceuticals Inc's market cap, and Under Armour Inc Class A is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | UAA | |
|---|---|---|
Market Cap | $14.64M | $2.79B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $8.14 |
52-Week Low | $0.53 | $4.17 |
Enterprise Value | $10.86M | $4.42B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Under Armour (UAA) trades at $6.75, down 0.59% on the day, with a mixed technical picture showing bullish moving averages but overbought RSI signals. Fundamentally, the company reported a net loss of $201.27 million in 2025 despite beating EPS expectations in two recent quarters, with revenue declining to $5.16 billion. Analyst sentiment is cautious with a consensus price target of $5.96, below the current price, and news highlights ongoing challenges in North America offset by international growth.
The outlook remains challenging with weak guidance for FY2027 and margin pressure, though international expansion and a recent Dodge collaboration offer potential catalysts. Key risks include persistent North American weakness, rising costs, and high debt levels. Investors face a stock with negative profitability metrics trading above analyst targets, suggesting limited near-term upside absent a significant operational turnaround.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
